# FY 2022: STRONG DELIVERY IN 2022, CONTINUING MOMENTUM IN 2023



### **Strong FY2022 performance**

FY LFL net revenue growth

23.8% FY AOP margin

#### FY2023 OUTLOOK

MID-SINGLE DIGIT GROWTH<sup>1</sup>

LFL net revenue


## MARGINS IN LINE OR SLIGHTLY ABOVE 2022<sup>2</sup>

Excl. c.80bps 2022 US Nutrition impact

#### Q4 2022: All GBUs in growth<sup>3</sup>

GROUP	+6.2%
HYGIENE	+1.3%
HEALTH	+6.7%
NUTRITION	+19.4%

## **Bigger business, stronger brands: + 8.2% CAGR vs 2019**<sup>7</sup>



#### **BROAD-BASED GROWTH**<sup>7</sup> **+7.6**% HYGIENE +9.0% durex\* Strepsils GAVISCON Mucinex HEALTH +8.1% Enfamil **NUTRITION9**

## From transformation to delivery **LEAD INDICATORS**



**In-market** competitiveness

**62**% Core CMUs gaining/holding share



**Brand Strength** 



#1 Trusted Infant Formula





+100BPS

Share of markets recognised as top tier by supplier partners<sup>5</sup>



Winning share across markets

Total Reckitt share of distribution points<sup>6</sup>





Recognised as a top employer in 7 countries













